Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr1.35 SEK
Change Today -0.02 / -1.46%
Volume 1.9M
As of 11:30 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

aerocrine ab - b (AEROB) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/14 - kr3.13
52 Week Low
12/29/14 - kr0.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AEROCRINE AB - B (AEROB)

Related News

No related news articles were found.

aerocrine ab - b (AEROB) Related Businessweek News

No Related Businessweek News Found

aerocrine ab - b (AEROB) Details

Aerocrine AB (publ), together with its subsidiaries, operates as a medical technology company primarily in Europe, the United States, North America, Asia, and the Oceania. The company offers NIOX MINO and NIOX VERO devices for checking inflammatory conditions in airways, as well as enhancing diagnosis, treatment, and follow-up of people with asthma. It serves research and pharmaceutical development companies, specialist doctors, outpatient and primary care clinics, and patients. The company was founded in 1997 and is headquartered in Solna, Sweden.

115 Employees
Last Reported Date: 02/20/15
Founded in 1997

aerocrine ab - b (AEROB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

aerocrine ab - b (AEROB) Key Developments

Aerocrine AB Announces Executive Changes

Aerocrine AB announced organizational changes: Morten Högholm Pedersen, MD PhD, will be joining the company in the role of chief technology officer effective June 1, 2015. Morten comes to Aerocrine from GN Otometrics A/S in Denmark where he held a number of different positions, most recently as VP Global R&D and Product Management. Morten will report to Scott Myers, CEO of Aerocrine. Caroline Andersson, Aerocrine’s General Counsel is being promoted to membership in Aerocrine’s executive leadership team effective immediately as recognition for her continued contribution to the business. Caroline will report to Marshall Woodworth, CFO of Aerocrine. In addition to her other duties and responsibilities Caroline will continue to serve in her role as secretary to the board of directors. Ken Marshall, President of Aerocrine Inc. and VP of Global Marketing will be leaving Aerocrine and the management group effective April 30, 2015. The roles that Ken filled will be handled by other members of the executive leadership team including Scott Myers who will be directly overseeing US Operations.

Aerocrine AB (publ) Reports Sales Results for the Year Ended December 31, 2014

Aerocrine AB (publ) reported sales results for the year ended December 31, 2014. For the year, net sales were SEK 166,222 million against SEK 136,168 million a year ago.

Aerocrine AB Receives FDA Clearance for NIOX VERO Bluetooth Wireless Enhancement

Aerocrine AB announces that clearance was received for its FeNO measuring device to operate wirelessly with BlueTooth technology in the US. The US FDA has granted Aerocrine AB regulatory clearance for NIOX VERO through a special 510k to utilize BlueTooth wireless technology to send FeNO measurements and patient data between the NIOX VERO and the healthcare providers computers. This cordless enhancement allows the device to go with a healthcare provider to a patient regardless of setting, either in an examination room, a pulmonary function lab or other setting. The clearance also allows the NIOX VERO to wirelessly transmit patient data to the computer for storage by the healthcare providers on the NIOX Patient software, Aerocrine's propriety data repository or other electronic medical record software the healthcare providers may be using. NIOX VERO is the company's next generation device for measuring Fractional Nitric Oxide (FeNO) levels in a clinical setting. This measurement has been found to be cost effective to aid in the diagnosis and management of allergic airway inflammation such as with asthma.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEROB:SS kr1.35 SEK -0.02

AEROB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEROB.
View Industry Companies

Industry Analysis


Industry Average

Valuation AEROB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEROCRINE AB - B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at